

Inhalational anesthetics:

| Drug | Characteristics | Uses | Effect on CVS | Effect on CNS | Effect on RS | advantages | disadvantages |
|---------------|--|--|--|---|--|--|---|
| Nitrous oxide | -Inorganic anesthetic gas -Inter nature with minimal metabolism -MAC value 104% (I need more than 100% to make 50% of patients tolerate the pain so we add another anesthetic agent) -hydrophobic | -Weak anesthetic -Good analgesic | -slightly depresses myocardial contractility -Stimulate CA so it mildly increases BP,CO,HR -Constriction of pulmonary vessels(might cause pulmonary HTN) | Increases CBF, ICP and cerebral oxygen consumption **the only one who increases the cerebral oxygen consumption . | -increases RR(rapid & shallow breathing) -Decreases tidal volume and minute ventilation -Minimal increases in CO2 -Decreases ventilator response to hypoxia | -Has analgesic effect -not a triggering agent of malignant hyperthermia | -N/V -Increases renal vascular resistance(decreases renal blood flow, GFR & UO) -Decreases hepatic blood flow -it diffuse into closed spaces that contain air **increase size of gases -inhibit vit. B12 metabolism ** BMS and neurological deficit |
| Halothane | -Most potent inhalational (MAC of 0.75%) anesthetic -Hydrophilic | Most potent inhalational anesthetic Depresses consciousness | -Significant myocardial depression (hypotension) -Reduce perfusion to coronary arteries(due to hypotension) -blunt reflexes -arrhythmogenic | -Increases CBF and ICP - <u>blunt autoregulation</u> - <u>decreases metabolic oxygen requirements</u> | Same as NO plus -potent bronchodilator -depress clearance of mucous>>post op hypoxia and atelectasis | - | -Triggering agent of malignant hyperthermia -decreases renal blood flow, GFR & UO (due to hypotension) -decreases hepatic blood flow -may cause hepatitis (fever, jaundice, hepatic necrosis and death) |

| Drug | Characteristics | Uses | Effect on CVS | Effect on CNS | Effect on RS | advantages | disadvantages |
|--------------------------------------|--|------|---|---|--|--|--|
| Enflurane (not frequently used) | MAC 1.68% | - | -Decreases contractility, HR -arrhythmogenic -decreases systemic vascular resistance(hypotension) | Epileptiform EEG patterns(increases EEG activity) | -Depressed ventilation(hypercarbia) -widens A-a gradient -bronchodilator | metabolism does not release a lot of hepatotoxic metabolites | Renal toxicity (metabolism release fluoride ion) |
| Isoflurane | Chemical isomer of enflurane MAC of 1.30% | - | - significant depression in systemic vascular resistance (severe hypotension) -coronary steal syndrome -minimal cardiac depression and preserve baroreflex(increase HR) | -increases CBF and ICP -decreases cerebral metabolic oxygen consumption | -Respiratory depression -decreases minute ventilation -blunt normal response to hypoxia and hypercapnia -irritate upper airway reflex -good bronchodilator | - | -decreases renal blood flow, GFR & UO (due to hypotension) -decreases hepatic blood flow |
| Desflurane | -MAC 6% -require special vaporizer -moderate potency -low solubility(short DOA) | - | -decreases systemic vascular resistance (hypotension) -unchanged or slightly depressed CO -rapid increase in concentration lead to transient increase in HR,BP,CA levels | -increases CBF and ICP -decreases cerebral metabolic oxygen consumption -associated with delirium with some pediatrics | -increases RR -Decreases tidal volume - Decreases ventilatory response to PaCO ₂ | - | -Dose dependant decrease in response to train of four and tetanic peripheral nerve stimulation. -degraded into Carbon monoxide -potentiate nondepolarizing NMBA's |

| Drug | Characteristics | Uses | Effect on CVS | Effect on CNS | Effect on RS | advantages | disadvantages |
|-------------|---|---|---|--|---|------------|--|
| Sevoflurane | Rapid increase in alveolar anesthetic concentration | -Smooth and rapid inhalation induction in peds and adult patients -adequate muscle relaxation for intubation in children | -decreases systemic vascular resistance (hypotension) - PROLONG QT INTERVAL -midly depress contractility | -slightly increase CBF and ICP -decreases cerebral metabolic requirements | -depress respiration -bronchodilator | - | -slightly decreases renal blood flow -decreases portal vein flow and increase hepatic artery flow - when metabolized by the liver it gives nephrotoxic end product(compound A) -potentiate NMBA's |

| | | | | | | | |
|--------------|--|--|--------------------------------|--|---|--|--|
| Quick recap: | | | *All causes cardiac depression | *All increases ICP and CBF *All decreases oxygen requirements except NO | *All causes respiratory depression, increases RR, decreases TV and Minute ventilation | | |
|--------------|--|--|--------------------------------|--|---|--|--|

**** obstetric effects:**

-produce dose dependant decrease in uterine contractility and blood flow.

-they cause uterine atony

-they rapidly cross the placenta and reach the fetus